CEBPA N-TERMINAL FRAME SHIFT

CI-VAR-00002850Explore in graph →CIViC 28

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia2
CEBPA N-TERMINAL FRAME SHIFT	(prognostic)	Prognostic	B	Supports Better Outcome	3	accepted	EID169 Remission duration was significantly longer in younger (16-60), cytogenetically normal AML patients with CEBPA PMID 14726504 · Fröhling et al., 2004 · Open in CIViC	civic
CEBPA N-TERMINAL FRAME SHIFT	OICR-9429	Predictive	D	Supports Sensitivity Response	3	accepted	EID1103 This preclinical study establishes that the p30 isoform of CEBPA expressed as a result of N-terminal truncating mutations preferentially interacts with WRD5, a component of the SET/MLL complex. Knockd… (full text at CIViC) PMID 26167872 · Grebien et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.